Skip to content

Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation

A Prospective Randomized Trial Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01939145
Enrollment
100
Registered
2013-09-11
Start date
2013-09-30
Completion date
2016-07-31
Last updated
2016-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound Infection

Keywords

hospital admission

Brief summary

This is a prospective, randomized trial comparing the outcomes for Prontosan versus normal saline as the solution for negative pressure wound therapy with instillation (NWPTi). Negative pressure wound therapy (NPWT) is a well established method of treatment for acute and chronic wounds. The combination of negative pressure with instillation of a solution is a relatively novel concept that has gained popularity and is currently used nationally and internationally. NPWTi is the standard of care for our division. Despite the growing use, there is limited information regarding the selection of the ideal instillation solution. This is a single site, investigator initiated, NPWTi study comparing the use of Prontosan with normal saline for the adjunctive treatment of the acutely infected wound that requires hospital admission. A total of 100 subjects will be included with 50 subjects in each treatment arm. The outcomes that will be measured are 1) number of operations, 2) length of hospital stay, 3) % of wounds closed prior to discharge, 4) time to closure prior to discharge, 5)% remained closed at 30 day follow-up, and 6) reduction of qualitative bacterial cultures. The results from this study will better characterize the most appropriate use of NPWTi.

Detailed description

Overview This is a prospective, randomized, comparative trial examining 2 different instillation solutions for NPWTi. All wound types that meet the eligibility criteria will be enrolled into the study. After enrollment, subjects will be randomized into either the Prontosan NPWTi group (n=50) or the normal saline NPWTi group (n=50). Data will be collected from inpatient hospital records. Outline of Study Procedures 1. Patients meeting the eligibility criteria requiring hospital admission for an infected wound will be identified. Demographic information will be obtained. 2. Informed consent will be obtained. 3. Subjects will be taken to the operating room for wound debridement within 72 hours of admission per standard of care (SOC). Further, antibiotic therapy and medical management will be performed per SOC. 4. Randomization into the Prontosan or normal saline instillation group will be conducted after the informed consent has been signed, but before the first operation. 5. For the first operating room visit the following will be conducted: 1. Pre- and post debridement qualitative cultures 2. Debridement performed in SOC fashion 3. Post debridement measurements 4. Application of NPWTi 6. For subsequent operating room visits the following will be conducted: a. Pre- and post debridement qualitative cultures b. Debridement performed in SOC fashion c. Post debridement measurements d. Application of NPWTi or closure i. The decision to close the wound will be determined by the clinician per SOC. ii. The technique utilized for closure will be determined by the clinician per SOC. 7. Subjects will discharged from the hospital a. Criteria for discharge will be per the judgment of the investigator per SOC 8. After hospital discharge, the subject will be followed in the outpatient wound clinic per SOC. Information from the one month follow-up period will be collected. Subjects will be exited from the study at that point. Subject Recruitment No active recruitment strategy will be employed. Patients who meet the eligibility criteria will be approached to participate into the study. Participation Completion and Discontinuation: Subjects may elect to discontinue participation at any time for any reason. Investigators may elect to remove the subject from participating at any time for any reason. Surgical Technique: Surgical debridement will be performed in SOC manner and is at the discretion of the investigator. Postoperative Care: Will be conducted in customary SOC fashion and is at the discretion of the investigator. The 30 day follow-up visit is part of SOC Application of Devices/Dressing: The device that will be utilized is the V.A.C. Ulta with Veraflo Technology (Kinetic Concepts Inc., San Antonio, TX). This is an FDA approved device that is indicated for wound care. The investigators currently use this device as the SOC for the inpatient management of the acutely infected wound. The device consists of a foam sponge applied to the wound surface with an adhesive drape that keeps it in place. This device applies subatmospheric pressure at -125mmHg to the wound surface. The instillation component includes the delivery of a topical solution at prescribed fashion to the wound surface. This solution is dwelled (no negative pressure during this interval) in the sponge for a specific duration and then is evacuated. Negative Pressure Wound Therapy: The setting for negative pressure will be -125mmHg, continuous setting, and moderate intensity. The application of the foam and drape will be conducted in the customary fashion. The negative pressure duration will be 2 hours. Prontosan: Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies. Normal Saline: Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.

Interventions

DRUGNormal saline

Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies

DEVICEProntosan

Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.

Sponsors

Georgetown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female greater than 18 years of age * Admission to the hospital for an infected wound * Diabetic, ischemic, neuropathic, venous, surgical wounds, any anatomical location * Subjects requiring serial (more than 1) operative debridement

Exclusion criteria

* Pregnancy * Patients with exposed bowel, brain matter, spinal cord * Patients with exposed peripheral bypass grafts * Known allergy or sensitivity to Prontosan or components of NPWT * Known allergy or sensitivity to adhesives * Uncontrolled bleeding disorders/coagulopathy * Wounds that tunnel to unexposed areas * Malignancy

Design outcomes

Primary

MeasureTime frameDescription
Number of Operating Room VisitsPatients will be followed during their hospital stay which is an average of approximately 2 weeks.Compare the number of operative room visits between Prontosan NPWTi and normal saline NPWTi.

Secondary

MeasureTime frameDescription
Hospital Admission Length of StayPatients will be followed during their hospital stay which is an average of approximately 2 weeks.Compare the hospital admission length of stay between Prontosan NPWTi and normal saline NPWTi.

Other

MeasureTime frameDescription
Time to ClosurePatients will be followed during their hospital stay which is an average of approximately 2 weeks.Compare the percent of wounds closed and the time to closure during the hospital admission and up to one year after discharge between Prontosan NPWTi and normal saline NPWTi.
Wound Recidivism30 days post discharge from hospitalCompare the percent of wounds that remained closed 30 days and up to one year after discharge between Prontosan NPWTi and normal saline NPWTi.
Bacterial Culture ResultsPatients will be followed during their hospital stay which is an average of approximately 2 weeks.Compare the qualitative bacterial culture results between Prontosan NPWTi and normal saline NPWTi.

Countries

United States

Participant flow

Participants by arm

ArmCount
Normal Saline
The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation. Normal saline: Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
49
Prontosan
The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation. Prontosan: Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
51
Total100

Baseline characteristics

CharacteristicTotalProntosanNormal Saline
Age, Continuous58.37 years
STANDARD_DEVIATION 14.09
55.94 years
STANDARD_DEVIATION 13.9
59.64 years
STANDARD_DEVIATION 15.4
Gender
Female
29 Participants8 Participants21 Participants
Gender
Male
71 Participants43 Participants28 Participants
Race/Ethnicity, Customized
African America
42 participants21 participants21 participants
Race/Ethnicity, Customized
Asian
6 participants5 participants1 participants
Race/Ethnicity, Customized
Caucasian
45 participants23 participants22 participants
Race/Ethnicity, Customized
Hispanic
3 participants1 participants2 participants
Race/Ethnicity, Customized
Missing/declined
3 participants1 participants2 participants
Race/Ethnicity, Customized
Other
1 participants0 participants1 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
14 / 4923 / 51
serious
Total, serious adverse events
2 / 493 / 51

Outcome results

Primary

Number of Operating Room Visits

Compare the number of operative room visits between Prontosan NPWTi and normal saline NPWTi.

Time frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.

ArmMeasureValue (MEAN)Dispersion
Normal SalineNumber of Operating Room Visits2.5 Operative Room VisitsStandard Deviation 0.9
ProntosanNumber of Operating Room Visits2.8 Operative Room VisitsStandard Deviation 0.9
Secondary

Hospital Admission Length of Stay

Compare the hospital admission length of stay between Prontosan NPWTi and normal saline NPWTi.

Time frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.

ArmMeasureValue (MEAN)Dispersion
Normal SalineHospital Admission Length of Stay13.6 daysStandard Deviation 11.7
ProntosanHospital Admission Length of Stay14.5 daysStandard Deviation 9
Other Pre-specified

Bacterial Culture Results

Compare the qualitative bacterial culture results between Prontosan NPWTi and normal saline NPWTi.

Time frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.

Other Pre-specified

Time to Closure

Compare the percent of wounds closed and the time to closure during the hospital admission and up to one year after discharge between Prontosan NPWTi and normal saline NPWTi.

Time frame: Patients will be followed during their hospital stay which is an average of approximately 2 weeks.

Other Pre-specified

Wound Recidivism

Compare the percent of wounds that remained closed 30 days and up to one year after discharge between Prontosan NPWTi and normal saline NPWTi.

Time frame: 30 days post discharge from hospital

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026